The Refill #3: Oral GLP-1 now on the market

Wegovy® is now available as a once-daily pill — and that changes the conversation around obesity treatment, cardiovascular risk reduction, access, and adherence. In this week’s Refill, we revisit our original GLP-1 deep dive and add the latest updates: ✔️ FDA approval details ✔️ Oral vs injection dosing ✔️ Clinical trial data ✔️ Cost comparisons ✔️ Side effects ✔️ Who this impacts most Same episode. New context. Because medicine doesn’t stand still. 🎙️ Listen wherever you get your podcasts. ⭐ Rate, review & follow — new episodes drop Mondays. #MedicalMediaMixer #GLP1 #Wegovy #ObesityMedicine #CardiovascularHealth #RefillEpisode #Semaglutide 📚 Sources FDA Orange Book. 2026. Wegovy® (semaglutide) FDA Drug Label. Updated December 22, 2025. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025. Rubino D, Abrahamsson N, Davies M, et al. STEP 4 Trial. JAMA. 2021. Ryan DH, Lingvay I, Deanfield J, et al. SELECT Trial. Nature Medicine. 2024. Schweitzer K. What to Know About the Wegovy Pill for Obesity. JAMA. 2026. AACE Consensus Statement 2025 Update. Endocrine Practice. Episodes every Monday ⭐️ Subscribe, Rate and Review! 🍸 Recipes drop on socials Discounts: 15% off Comfrt apparel Purple Carrot: 40% off your first box ClassPass: 2 weeks free 15% off non-alcoholic spirits at The Zero Proof 💳 Support us on Patreon | ☕️ Buy Me a Coffee Contains affiliate links. We may earn a commission at no additional cost to you.